During a panel at Fierce JPM Week, coinciding with the J.P. Morgan Healthcare Conference in San Francisco, industry experts discussed the intricacies of executing a successful biotech IPO in the current market. The episode of The Top Line, moderated by Gabrielle Masson from Fierce Biotech, featured insights from leaders including Septerna CEO Jeffrey Finer, Rapport Therapeutics CFO Troy Ignelzi, Sofinnova Investments’ Maha Katabi, and Morgan Stanley’s Chirag Surti. They explored the characteristics of biotechs that went public in 2024, strategies for effective IPOs, and market expectations for 2025.